Apellis Pharmaceuticals
Apellis Pharmaceuticals develops life-changing medicines for debilitating diseases driven by complement, offering two approved medicines targeting C3 and nearly a dozen clinical and pre-clinical programs. The company has a global presence and supports employees with flexible working models and comprehensive rewards programs.
Services
Apellis Pharmaceuticals is dedicated to developing life-changing medicines for a wide array of debilitating diseases driven by complement. This dedication is evident through their comprehensive control of diseases with high unmet needs by targeting C3, the central protein in the complement cascade. The company offers flexible and remote working models, ensuring that the individual needs of its employees are met. Additionally, Apellis supports its employees and their families through a total rewards program that fosters health, well-being, and future success.
Approved Medicines
Apellis Pharmaceuticals has released two approved medicines targeting C3, providing innovative solutions for diseases driven by the complement system. These medicines are designed to control and manage diseases with significant unmet medical needs, enhancing the quality of life for patients with debilitating conditions. The company's approach focuses on comprehensive disease control by intervening at the central protein in the complement cascade.
Clinical Programs
Apellis Pharmaceuticals is actively engaged in nearly a dozen clinical and pre-clinical programs. These programs span across various medical fields, including rare diseases, retinal diseases, and neurological conditions. This diverse pipeline underscores Apellis’s commitment to advancing medical science and delivering therapeutic options for patients suffering from serious and often overlooked diseases.
Global Presence
Apellis Pharmaceuticals maintains a strong global presence with offices located in the United States, Switzerland, Germany, and Australia. This international footprint allows the company to operate efficiently and collaboratively across different regions, bringing its innovative treatments to a global patient population. The company ensures that its operations and personnel comply with ethical business standards through a Supplier Code of Conduct that promotes responsible sourcing.